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As our knowledge of host-microbial interactions within the
oral cavity increases, future treatments are likely to be more
targeted. For example, efforts to target a single species or key
virulence factors that they produce, while maintaining the
natural balance of the resident oral microbiota that acts to
modulate the host immune response would be an advantage.
Targeted approaches may be directed at the black-
pigmented anaerobes, Porphyromonas gingivalis and
Prevotella intermedia, associated with periodontitis. Such
pigments provide an opportunity for targeted phototherapy
with high-intensity monochromatic light. Functional
inhibition approaches, including the use of enzyme inhibitors,
are also being explored to control periodontitis. More general
disruption of dental plaque through the use of enzymes and
detergents, alone and in combination, shows much promise.
The use of probiotics and prebiotics to improve
gastrointestinal health has now led to an interest in using
these approaches to control oral disease. More recently the
potential of antimicrobial peptides and nanotechnology,
through the application of nanoparticles with biocidal, anti-
adhesive and delivery capabilities, has been explored. The
aim of this review is to consider the current status as regards
non-conventional treatment approaches for oral infections
with particular emphasis on the plaque-related diseases.
Introduction
The oral cavity provides habitats for a wide diversity of micro-
organisms including bacteria, yeasts and viruses; members of all
groups being associated with oral infections. Bacteria are the pre-
dominant components of this resident microflora, and the diver-
sity of species found in the oral cavity reflects the wide range of
endogenously derived nutrients, the varied types of habitat for
colonization including surfaces on the teeth, mucosa and tongue,
and the opportunity to survive as a biofilm.1,2 However, the rela-
tionship between this microflora and the host can be disrupted in
a number of ways, resulting in the development of disease of the
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oral structures. These are mainly localized and include dental car-
ies (dental decay), gingivitis, periodontitis (gum disease), candidi-
asis, endodontic (root canal) infections, orthodontic infections
and peri-implantitis.3
Most bacterial infections within the oral cavity are polymicro-
bial in nature, and it is quite unusual to find any that are clearly
due to a single species. The relative contribution of different bac-
terial components in such infections is thus difficult to deter-
mine. Oral infections may arise either from an endogenous
source, i.e., one yielding microorganisms normally found in the
mouth, such as the main plaque-related diseases of dental caries
and periodontal disease, or from an exogenous source yielding
microorganisms not normally found as part of the oral microflora
(e.g. syphilis, tuberculosis). Plaque-related diseases are probably
the most common bacterial diseases occurring in man. Dental
caries is a destructive condition of the dental hard tissues that, if
unchecked, can progress to inflammation and death of vital pulp
tissue, with eventual spread of infection to the periapical area of
the tooth and beyond. The disease process involves acidogenic
plaque bacteria, including Streptococcus mutans, Streptococcus
sobrinus, Lactobacillus spp., Actinomyces spp and Bifidobacterium
spp.,3,4 whereas periodontal diseases can involve both the soft
and hard tissues and are the most common inflammatory
destructive conditions that affect man. They are initiated by com-
ponents of the plaque that develops on the hard root surface adja-
cent to the soft tissues of the supporting periodontium and may
be confined to the gingiva (gingivitis) or extend to the deeper
supporting structures with destruction of the periodontal liga-
ment and the alveolar bone that supports the teeth (periodonti-
tis). Such loss of attachment, with associated periodontal pocket
formation, may ultimately lead to loosening and loss of the
affected teeth. Porphyromonas gingivalis, Prevotella intermedia and
Aggregatibacter actinomycetemcomitans are regarded as the major
pathogens in advancing periodontitis.5 Furthermore it has been
recently suggested that there is an association between the oral
microbiota and systemic disease, such as cardiovascular disease
and complications during pregnancy.6,7
The prevention of dental caries and the periodontal diseases is
traditionally targeted at the mechanical or non-specific control of
dental plaque as this is the precipitating factor. This is carried
out to maintain plaque at levels compatible with health and so
prevent the breakdown of microbial homeostasis which increases
disease risk. However, the individual response of the host and
other confounding factors can influence disease initiation and
progression. Antimicrobial and antiplaque compounds in oral
care products represent a valuable complement to mechanical
plaque control. Such strategies should ideally prevent plaque
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biofilm formation without affecting the biological equilibrium
within the oral cavity, which is inhabited by up to 1000 different
species of bacteria at 108–109 bacteria per mL saliva or mg dental
plaque.8 However, with ever increasing antibiotic resistance and
a public desire for more ‘natural’ therapies, there is an increased
need to minimise antibiotic use and develop novel treatments for
oral diseases that do not involve conventional antimicrobial
agents.
Dental Plaque Disruption
Enzymes
A number of oral streptococci, including Streptococcus mutans,
produce a range of water-soluble and insoluble glucan extracellu-
lar polysaccharides in vivo.9 The different types of glucans are
synthesized by different glucosyltransferases, particularly a-(1–
>3)-linked glucans (synthesized by GTF B) and a-(1–>6)- and
a-(1–>3)-linked glucans (synthesized by GTF C).9 The water
insoluble types (a-1!3) are thought to contribute to the cario-
genicity of the plaque at a site through its physical retentive
nature, its ability to provide a large diffusion volume for dietary
sugars and as a substrate for further adhesion of bacteria. Conse-
quently a desirable goal would be to distrupt this feature of the
plaque biofilm with glucanase enzymes (dextranase and muta-
nse). Both dextranases and mutanases are able to suppress the
accumulation of dental plaque in human volunteers, in animals
or in vitro depending upon the experimental system
employed.10-12 Such enzymes would be applied directly to dental
plaque where GTFs are still active, which raises the question of
their likely longer term efficacy. However, these enzymes have
been found, to influence glucan synthesis by GTFs themselves in
terms of linkage remodelling and branching and this appears to
have an impact on the formation, maturation and physical prop-
erties of the glucans present.13 Consequently there is reason to
believe that such enzymes could be a valuable addition to the
control of the plaque biofilm.
Another approach to enzymic disruption of biofilms is the use
of deoxyribose nucleases (DNAases). While it has been known
since the 1940’s that bacteria can release DNA extracellularly,14
it is only relatively recently that biofilms have been found to con-
tain a significant amount of intact extracellular DNA (eDNA).
This is present either because of cell death or active secretion, or
both, and there is now strong evidence that this DNA contributes
to the matrix of the biofilm, an important structural component
of its scaffold.15 It seems logical then that application of exoge-
nous DNAases could degrade this scaffold and so provide a
means of disrupting the integrity of the biofilm and/or its
growth. Indeed, a number of workers recently have shown that
DNAase treatment of in vitro biofilms can weaken the structure
and result in release of bacteria.16-18 However, DNAases are rela-
tively expensive to produce currently and for application on a
large clinical scale improvements in production methods will be
required. Nonetheless, enzymic disruption of the plaque biofilm
does look a promising way forward for the future.
Detergents
An alternative to enzymic disruption of the biofilm matrix is
chemical disruption and a number of ionic detergents can bind
to bacteria and their matrix, which could be effective biofilm dis-
rupting agents. While cationic detergents have been used in com-
mercial products for some years, often referred to as pre-brushing
mouth washes, there have been conflicting claims about their
effectiveness. Despite the numerous claims and counterclaims,
recent systematic reviews of the literature have failed to show
clear advantages of detergent mouthwashes over good oral
hygiene instruction on the removal of dental plaque.19,20 How-
ever, it is possible that the failure of these products to realize their
potential has been due to the mode of their delivery, since the
tendency is for the agent to bind largely to the surface of the bio-
film. One of the most commonly used agents in such pre-brush-
ing mouthwashes is cetylpyridinium chloride and recent work
has concentrated on exploring alternative delivery methods.
These methods include incorporation of cetylpyridinium chlo-
ride within cholesterol liposomes21 and in nanoemulsions.22
Although not yet tested clinically, the nanoemulsions look partic-
ularly effective since in vitro testing has shown inhibitory effect
on S. mutans biofilms23 and using a multispecies biofilm grown
in an artificial mouth system, showed good penetration into the
biofilm. Furthermore, it was superior to chlorhexidine in reduc-
ing the depth of artificial carious lesions and in mineral loss in
this system.22 Perhaps combinations of nanoemulsions of deter-
gents and enzymic disruption agents, to aid even more effective
penetration, would provide optimum plaque disruption.
Light-activated Killing
The fact that bacteria can be killed by light in the presence of a
sensitizing agent was discovered 100 years ago by Reitz in 190824
but it is only recently that the possibility of using this technology
for the control of oral infection has been considered.25 The pro-
cess of killing microorganisms with light depends upon the gen-
eration of cytotoxic singlet oxygen and OH radicals (reactive
oxygen species; ROS), which are formed by the excitation of a
photactivateable agent or sensitizer. The result of excitation is
that the sensitizer moves from its electronic ground state to a trip-
let state that then interacts with cell components to generate
ROS.26 One of the particular values of light-activated killing is
that resistance to the action of singlet oxygen is less likely to
become a major concern and spread widely, unlike that experi-
enced with chemical antimicrobial agents. Despite the general
truth of this, recent data have shown that spontaneous mutants
that are resistant to photoactivated killing can arise.27
A sensitizer should bind avidly to the bacterial cell and/or be
taken up by it, thus a number of sensitisers are highly charged
molecules,28 the most commonly tested of which have been tricy-
clic dyes, (e.g., methylene blue, erythrosine), phenothiazine dyes
(e.g. toluidine blue O), tetrapyrroles (e.g., porphyrins) and furo-
coumarins (e.g. Psoralen). Table 1 shows a number of the sensi-
tisers that have been used in recent studies, some of which are
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tried and tested agents while others are newly synthesized variants
of previously used categories of agents (e.g., porphyrins).
A sensitizer ideally should absorb light at red to near-infrared
wavelengths because longer wavelengths tend to be more penetra-
tive. However, red light sources with narrow wavelength band-
widths tend to be expensive, whereas LED light sources (blue or
red) are commonly available in dental surgeries so finding sensi-
tizing agents that are compatible with such light sources would
be an advantage for use against oral infections. These dental LED
lights are used to cure resin-based composite restorative materials.
A dental light was used to assess killing of S. mutans, A. actinomy-
cetemcomitans and Enterococcus faecalis by a commercial prepara-
tion of haematoporphyrin sensitizer (Photosan).42 The Photosan
dye was readily taken up by the Gram-positive species but not by
A. actinomycetemcomitans unless 10% EDTA was used to aid
entry of the dye through the outer membrane. Around 3 to 4
log10 reduction in viable count was achieved, which demonstrates
the potential of these commonly used light sources for photoacti-
vated killing. However, others have reported that dental LEDs
are not as effective at killing A. actinomycetemcomitans as the
more powerful indium-gallium-aluminum-phosphate lasers.41
Inefficient killing of Gram-negative species relative to Gram-pos-
itive by photoactivation has been known for almost 30 years43 as
well as the value of adding a membrane-disrupting agent to
enhance access of the photo-sensitizer. However, other effective
approaches include using agents with strong cationic charge to
enhance binding to Gram-negative bacteria44 and liposome
encapsulation to enhance delivery by fusion with the mem-
brane.45,46 In each case though, the degree of killing will still
depend upon the efficiency of the photosensitizer being used.
The majority of work on light-activated killing has been per-
formed using suspensions of planktonic bacteria; however a cru-
cial requirement for application to many disease states, including
the dental plaque-related diseases, is the ability to kill microor-
ganisms growing as biofilms. In this phenotype, microorganisms
are known to be much more resistant to killing by chemical
agents, including antibiotics, and so assessment of efficacy should
always include assays on biofilms. Over twenty years ago, Wilson
et al47 showed that oral bacteria could be killed by low power
laser radiation in the presence of methylene blue both as plank-
tonic suspensions and when growing as a biofilm on an agar sur-
face. Whether these are true biofilms has been the subject of
debate for some years, but more recently in vitro biofilm-grown
S. mutans cells were killed by up to 3 log10 fold when treated
with erythrosine and white light (500–650 nm).48 Photoacti-
vated killing has also been assessed against E. faecalis biofilms
grown for 4 days and 4 weeks within the root canals of extracted
teeth and while this did reduce bacterial viability, maximal
improvement was gained when it was combined with chemome-
chanical treatment. Nonetheless, dental LEDs with common
blue light-absorbing photosensitizer dyes can eradicate E. faecalis
biofilm, although requiring increased sensitizer concentration
over that required to kill planktonic bacteria.36
There are a number of other aspects that should be considered
in relation to the therapeutic use of light-activated killing of bio-
films on host surfaces: (1) direct toxicity of the sensitizer, (2)
indirect toxicity of the sensitizer in terms of “by-stander” damage
to adjacent host cells, (3) penetration into the biofilm, and (4)
light exposure time required to kill bacteria within in vivo bio-
films. Answers to all of these questions are not readily available or
universally applicable to all bacteria. However, in relation to (1)
and (2) it is known that sensitizing agents can give rise to photo-
toxic effects on keratinocytes and fibroblasts49 and phototoxic
reactions in experimental animal oral tissues have been recorded,
although the effect appears to be short lived.50 The photosensi-
tizer erythrosine has an advantage over some other dyes because
it is currently used in dentistry to visualize dental plaque in vivo,
and so its lack of direct toxicity on the host is well established.
For phototherapeutic use in periodontitis, the dye needs to be
applied subgingivally prior to fiber-optic laser light activation.
However, in disease the periodontal site has a marked flow of
serum into the pocket (gingival crevicular fluid) and most photo-
sensitizers lose a degree of activity in the presence of extraneous
protein and some have virtually no effect in the presence of
serum, blood or saliva. This is because the agents complex with
proteins and host cells in the crevicular fluid which effectively
competes for binding to bacteria. Despite these theoretical limita-
tions, a commercial PDT system designed for use in periodontal
patients (Periowave, Ondine Biopharma, Vancouver, Canada)
has been shown to provide some clinical advantage when com-
bined with conventional root surface debridement (RSD) com-
pared to RSD alone.51,52 However, ideally mono-therapy by
PDT for periodontitis would be advantageous as PDT mono-
therapy has been shown to provide not only some improvement
in clinical signs but also reduction of local proinflammatory cyto-
kines and reduction in numbers of P. gingivalis and A. actinomy-
cetemcomitans.53 Nonetheless, the modest clinical improvements
achieved so far might be enhanced if methods for better retention
of the photosensitiser at the site could be found.
An approach that might achieve this is the use of nanopar-
ticles to deliver the ROS-generating system. Such systems
may have better sustainability in the subgingival environment
by being taken up into the plaque biofilm.54 Nanoparticles
that contain a conventional sensitizer and have antibacterial
action have been known for some time, for example the
Table 1. Example photosensitisers used in recent studies
Sensitizer Reference
Phenalen 1 29
Indocyanine green 30
Methylene blue 31,32
Toluidine blue ortho 33
Malachite green 34
Eosin-Y 35,36
Rose bengal 35,36
Curcumin 36
Nile blue derivatives 37
BIODIPY derivatives 38
Dicationic 5,15-diarylporphyrins 39
Haematoporphyrin monomethyl ether 40
Meso-substituted porphyrins 27
Radachlorin 41
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polysiloxane polymers containing embedded methylene blue
and gold nanoparticles described by Perni et al.55 However,
more recently similar systems have been developed that are
independent of a chemical sensitizer. Chong et al.56 produced
nanoparticles of a boron-dipyrromethene polymer that is cat-
ionic and that on photoactivation with white light generates
ROS at the particle surface.
Selective killing
Another approach for phototherapy is to take advantage of an
‘intrinsic sensitizer’ within the target bacteria, rather than relying
on the vagaries of dye binding and penetration. Several studies
have indicated the use of porphyrins as potential antimicrobial
agents and these can interfere with bacterial heme uptake systems
as well as generate ROS. Porphyrins are metal-chelating groups
and the oral anaerobes belonging to the Porphyromonas and Pre-
votella genera include species that accumulate heme compounds
on their cell surface in the form of a black pigment. Soukos
et al57 found that light in the wavelength range 380–520 nm
rapidly and selectively killed oral black-pigmented bacteria in
pure cultures. They hypothesized that the killing effect was due
to photo-excitation of porphyrins on the surfaces of these bacte-
ria, so making the effect quite specific. A similar phenomenon
has been found with A. actinomycetemcomitans in which blue light
without sensitizer reduced the viable count of a suspension by 5
log10, which appeared to be due to endogenous flavin-like or por-
phyrin-like compounds.58 In contrast there was no effect of blue
light on Escherichia coli because no singlet oxygen species was
generated presumably because no similar endogenous photosensi-
tisers were detected.58 Exploiting natural porphyrins as photosen-
sitisers certainly has value if it can be successfully applied to
subgingival plaque in patients with periodontitis. Indeed, light
applied to the oral surfaces of periodontitis patients shows a selec-
tive reduction of 4 black-pigmented species.57
Functional Inhibition
As summarised above and for obvious reasons, the approach
most often taken for treating infection is to attempt to kill or
eradicate the offending organisms. However, where the identity
of the offending organism is less clear, for example in chronic
infections associated with complex mixtures of organisms (viz.
periodontitis), an alternative approach to therapy that maintains
an element of homeostasis of the population would be beneficial.
One approach, as explained later, is to replace the pathogenic
strain with a non-pathogenic strain (‘replacement therapy’).
Another is to consider a disease process in terms of the “virulence
burden” that the host experiences, regardless of the identity of
the contributing organisms. Limiting the functionality of these
critical virulence factors would allow the host’s defense mecha-
nisms to deal with the organisms present as a collection. The con-
cept moves away, therefore, from targeting specific organisms or
groups of organisms and toward targeting their products. Of
course, a disadvantage of this approach is that knowledge of the
principal virulence factors involved is a necessity.
Microbial proteases
One important class of bacterial virulence factors that are a
potential target for such a therapeutic approach is extracellular
proteases. Some of these have broad specificity, e.g. trypsin-like
proteases,59,60 while others are very specific (e.g., IgA protease,
which cleaves the hinge region of the immunoglobulin mole-
cule).61 There are 4 main classes of proteases; (1) serine proteases,
(e.g., trypsin-like, elastase), (2) cysteine proteases (e.g., gingi-
pains), (3) Aspartic proteases, (e.g., Candida albicans Saps), and
(4) metallo-proteases (e.g., microbial keratinases). Individually or
collectively these classes of enzymes play critical roles in infection,
both in terms of direct tissue destruction and more subtle effects,
such as activation of host proteases,62 inactivation of host prote-
ase inhibitors63 and disruption of cytokine networks. Another
important class of proteases in terms of microbial physiology is
the caseinolytic proteases that are not extracellular. These are
termed Clp proteases and they regulate protein quality and turn-
over including damaged proteins and transcriptional regulators.64
Clp-dependent proteolysis has been implicated in expression of
extracellular virulence factors, such as cytotoxins, and in resisting
adverse conditions inside host cells. Loss of Clp functionality has
been shown to render some pathogens more sensitive to innate
host defenses, including host antimicrobial peptides.65 Thus,
bacterial proteases are a useful target for therapeutics not only to
prevent their direct and indirect effects on host tissue and sys-
tems, but also because proteases fulfil a nutritive and defensive
role for the bacteria.66,67 Table 2 shows a series of example target
proteases of pathogenic bacteria, including certain oral
organisms.
Protease inhibitors
Inhibitors of therapeutic value are usually thought of as inor-
ganic/synthetic agents; however, they could also be “host
products” appropriately manipulated. A known example of a
host product is salivary histatin 5, which is an inhibitor of both
host and bacterial proteases implicated in periodontal disease.68
This antimicrobial (host defense) peptide also shows general
inhibitory effect against a range of organisms but particularly
fungi69,70 and the domain responsible for this anti-protease activ-
ity resides in a 14 residue C-terminal sequence. The peptide is
known to have an effect at mucosal surfaces that are readily acces-
sible to saliva, but periodontal sites are not normally penetrated
by salivary secretions. Thus, histatin would have to be used as a
therapeutic agent directly applied subgingivally in a suitable
vehicle.
The main classes of inorganic or synthetic inhibitors are chela-
tors, oxidizing agents, thiol-blocking agents, heavy metal ions,
methanethiosulfonates and organo-mercurials. Chelators, such as
EDTA, are common inhibitors of metalloenzymes, while lantha-
nides inhibit Ca2C-requiring proteases, because Ln3C ions replace
Ca2C and form an inactive enzyme-substrate complex.71,72 How-
ever, lanthanides also activate the conversion of trypsinogen to
trypsin.73 A recently discovered inhibitor of Clp proteases was
identified by high throughput screening as N- (1- (2-aminoethyl)
-lH-tetrazol- 5-yl) -3-chlorobenzamide and which is termed
F2.74 This inhibitor has pleiotropic effects on the bacterial cell
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because the Clp protease regulates a wide range of genes75 and
also F2 has been shown to increase the effectiveness of bacterial
killing by human whole blood, indicating that this compound
can augment innate immune defenses.74 Consequently the thera-
peutic effect of F2 may be enhanced at tissue sites where high lev-
els of antimicrobial peptides are produced e.g periodontal sites.
An important role for Clp proteases in the virulence of P.
gingivalis has been identified. First, ClpC and ClpXP expression
is elevated in biofilms and the ClpC and XP proteases are neces-
sary for internalization into epithelial cells. ClpB is required for
intracellular survival.76 Consequently, inhibitors of the Clp pro-
teases, such as F2, have potential applications in the treatment of
periodontitis.
P. gingivalis gingipain proteases
The gingipain proteases of the periodontal pathogen P. gingi-
valis are a particularly interesting target in relation to periodonti-
tis. There are 2 major gingipains, arginine-specific gingipain
(RgpA & B) and a lysine specific gingipain (Kgp). Despite the
fact that the Rgps are in approximately a 3-fold excess over
Kgp,77 the latter appears to be the most important enzyme for
virulence and for nutrient assimilation. The specific mechanism
(s) by which this enzyme is involved in these functions is not
absolutely clear but a kgp mutant has been shown to be unable to
accumulate haemin at the cell surface (loss of black pigmenta-
tion) which results in reduced oxygen tolerance and reduced viru-
lence factor expression.78,79 In addition, the inability to sequester
iron may lead to the down regulation of other traits required for
maximal expression of virulence in vivo. Consequently, Kgp
appears to be a useful target enzyme for direct inhibition and
work by Curtis et al.80 developed and tested an inhibitor specific
for Kgp (1- (3-phenylpropionyl) piperidine-3 (R, S)—carboxylic
acid—[4-amino-1 (S)-(benzothiazole-2-carbonyl) butyl] amide
(A71561)). This agent showed no inhibition of the Rgps, and
did not inhibit growth of P. gingivalis on complex media; how-
ever, pretreatment of P. gingivalis with this agent prior to infec-
tion in a murine model significantly reduced pathogenicity. In
contrast, pretreatment of P. gingivalis with an Rgp inhibitor, leu-
peptin, did not affect virulence.
Despite this, it is known that the RgP gingipains act in concert
with Kgp gingipain to contribute to the entire virulence of the
organism, particularly through disruption of the host comple-
ment system.81 Therefore, a single agent that inhibits both gingi-
pain proteases has clinical therapeutic potential. Kataoka et al82
recently developed such a dual inhibitor through structure-based
drug design. It has potent antibacterial activity against P. gingiva-
lis in vitro and reduced gingival inflammation in a beagle dog
periodontitis model.
Probiotics and Prebiotics
Probiotics
Probiotics are live microorganisms which, when administered
in adequate amounts, confer a health benefit on the host. Probi-
otics have been used successfully to control gastro-intestinal dis-
eases and appear to act through colonisation resistance and / or
immune modulation. Likewise, studies also suggest that probiot-
ics have the potential to modify the oral microbiota. However
these may only be successful over the short term. Experimental
studies and clinical trials have demonstrated that certain gastroin-
testinal bacteria, including Lactobacillus and Bifidobacterium spp,
Table 2. Selected examples of bacterial proteases, their preferred cleavage sites and example inhibitors
Enzyme Source Cleavage site Inhibitor
Serine and Cysteine proteases
Glutamyl endopeptidase I Staphylococcus aureus Glu-Phe or Glu-Val None
Exfoliative toxin A S. aureus Glu-X
IgA1-speciﬁc protease Haemophilus inﬂuenzae Neisseria meningitidis Pro-Ser, Pro-Thr None speciﬁc
C5a peptidase Streptococcus agalactiae Streptococcus pyogenes His-Lys None speciﬁc
Trepolisin Treponema denticola Phe-X None speciﬁc
Prolyl tripeptidyl-peptidase P. gingivalis X-Y-Pro-X None speciﬁc
Omptin E. coli Yersinia pestis Arg-Arg, Arg-Lys thiol-blocking agents
Clostripain C11 Clostridium histolyticum Arg-X, Lys-X oxidizing agents, thiol-blocking agents,
heavy metal ions
Gingipain R
Gingipain K P. gingivalis Arg-X
Lys-X
thiol-blocking agents 1-(3-phenylpropionyl)
piperidine-carboxylic acid-[4-amino-1(S)-
(benzothiazole-2-carbonyl)butyl] amide,
Sortase ubiquitous in Gram-positive bacteria Leu-Pro-X-Thr-Gly methanethiosulfonates or organo-mercurials
Clp peptidases Ubiquitous Met-Ala ATP-dependent
Metalloproteinase
Pseudolysin Pseudomonas aeruginosa Phe-X or Gly-Leu EDTA, EGTA, phenanthroline
Vibrio collagenase Vibrio parahaemolyticus X-Gly
Clostridium collagenases Clostridium perfringens X-Gly sulfonylated amino acid hydroxamates
Aeruginolysin Ps. aeruginosa Leu-Gly or Gly-Gly
Mirabilysin Proteus mirabilis Leu-Gly (in IgA)
Fragilysin Bacteroides fragilis Leu-Gly Gly-Leu EDTA, DTPA
Sialoglycoprotein endopeptidase H. inﬂuenzae Arg-Asp
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may also control the growth of oral microorganisms, including
cariogenic streptococci associated with disease.
Mechanisms of probiotic action within the oral cavity can
possibly be suggested from gastrointestinal studies83 whereby the
introduction of microorganisms as a therapeutic tool for the pre-
vention and treatment of dental caries and periodontal disease
could possibly act as follows within the oral environment.
1. Direct interactions within dental plaque. These could possibly
include the disruption of plaque biofilm formation through
competition for binding sites on host tissues and other bacte-
ria, and competition for nutrients. The production of antimi-
crobial compounds that inhibit oral bacteria may also be a
significant mechanism. It is known that lactic acid bacteria
produce a range of antimicrobial agents including organic
acids, hydrogen peroxide, low molecular weight antimicrobial
peptides, bacteriocins and adhesion inhibitors.83
2. Indirect probiotic actions within the oral cavity, including the
modulation of aspects of both innate and specific immune
function. Within this context, it is possible that lactic acid
bacteria can interact with immunocompetent cells, such as
macrophages and T-cells, leading to cytokine production and
subsequent effects on overall immunity.83
Lactobacillus rhamnosus CG,84 L. casei,85 L. reuteri86 and Bifi-
dobacterium DN-173 01087 have all demonstrated the potential
to alter colonisation of cariogenic bacteria and thus prevent den-
tal caries. The oral administration of probiotics has also been
explored in the control of periodontal disease. Krasse et al.88
demonstrated a reduction in plaque levels and gingival inflamma-
tion with the application of L. reuteri to subjects with moderate
to severe gingivitis. To achieve optimal effects, simultaneous use
of multiple species may be required as described using S. oralis,
S. uberis and a lactic acid-deficient variant of S. rattus, whereby
the probiotic mouthwash was able to markedly affect the levels of
cariogenic bacteria in saliva and periodontal pathogens in subgin-
gival plaque.89 However, although available data indicates an
effect of probiotics on the oral microbiota, a more limited effect
on clinical periodontal outcome measures is observed. There is a
need for clinical trials where probiotics are used as adjuncts to
standard periodontal treatment.
‘Replacement therapy’ based upon biotechnological
approaches has also been investigated. Techniques include gene
inactivation to remove metabolites that may harm the host and
the incorporation of genes to encode for antimicrobial com-
pounds, for example bacteriocins that inhibit the growth of
strains of the same species. Genetically modified bacteria, for
example S. mutans, are being considered for replacement therapy
in the control of dental caries. Using recombinant DNA method-
ology, a strain of S. mutans was made lactate dehydrogenase defi-
cient by the deletion of virtually all of the genetic sequence
encoding this activity. To then compensate for the resulting met-
abolic imbalance, an alcohol dehydrogenase gene from Zymomo-
nas mobilis was introduced. No detectable lactic acid during
growth was produced from the resulting clone. This strain was
also significantly less cariogenic than the parent strain in
gnotobiotic- and conventional-rodent models of disease. In addi-
tion it was found to colonise the teeth of conventional rats to the
same extent as the parent strain using both aggressive-displace-
ment and preemptive-colonisation approaches. The clone was
shown to be genetically stable and did not revert to producing
acid in both in vivo and in vitro test systems.90
Prebiotics
Prebiotic substances, non-digestible oligosaccharides and
other selectively fermented food ingredients have been used to
improve gastrointestinal health and are now receiving interest in
relation to oral applications. The main mechanism by which pre-
biotics act is assumed to be via facilitating proliferation of com-
mensal bacteria, with resulting probiotic effects.91 Some
prebiotics may also exert effects on the host mucosal immune
and inflammatory systems, independent of their effects on com-
mensal bacteria.91 Examples of prebiotics include inulin-type
fructans, maltodextrin, fructooligosaccharides and galactooligo-
saccharides. It is also known that the oral microflora of the child
is influenced to a large extent by diet. Within this context it is of
interest that human milk contains oligosaccharides that have pre-
biotic characteristics.92
Antimicrobial Peptides
Antimicrobial (host defense) peptides (AMPs) are a diverse
group of molecules and include defensins, cathelicidins, histatins,
neuropeptides, peptide hormones, and many other proven and
putative peptides. These peptides are produced by many tissues
and cell types; with phagocytic and epithelial cells as the predom-
inant source. Peptide concentrations from these cells increase sig-
nificantly following infection or injury. Human saliva and
gingival crevicular fluid contains at least 45 individual antimicro-
bial proteins and peptides that can be classified into different
functional classes93 (Table 3). The majority of AMPs fall within
the cationic peptide group and are generally defined as being 12-
50 amino acids in length, with a net positive charge of C2 to C7
and up to 50% hydrophobic amino acids. This provides for an
amphipathic design, consisting of spatially separated hydropho-
bic and charged regions, and permits intercalation of the peptide
with microbial membranes. Direct antimicrobial activity against
microorganisms has been considered, until recently, their pri-
mary function. However, many peptides may have no direct
inhibitory activity at their physiological concentrations found
within oral fluids. Conversely, AMPs may have an antimicrobial
effect at the epithelial surface of the gingivae or at the secretion
site from neutrophils where the local concentration could be
higher than that found in oral fluids.
There is now increasing evidence that AMPs are multifunc-
tional molecules of fundamental importance in host defense,
modulating between aspects of the innate and adaptive immune
systems. Recently, it has become apparent that AMPs stimulate a
wide range of effects relevant to inflammation, innate immunity
and adaptive immunity. This includes effects on innate immune
cells, including neutrophils and epithelial cells, and in those cells
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that bridge the innate and adaptive immune systems, including
monocytes, macrophages and other antigen-presenting cells.
These peptides have been shown to modify cellular functions
such as chemotaxis, apoptosis, gene transcription and cytokine
production. In addition, they have been shown to have roles in
the stimulation of wound healing and angiogenesis.94 The use of
AMPs to control oral infections including periodontitis may
therefore depend upon direct antibacterial, anti-inflammatory
and/or immune modulatory actions.
Functional and structural diversity of AMPs and other innate
defense molecules may well be necessary to help protect the oral
epithelia from infection and maintain the balance of commensals
and opportunistic pathogens required for health. Furthermore,
AMP expression is partly regulated by the oral microbiota,95
with the commensal bacteria often inducing peptide expression
above that demonstrated with the more pathogenic species. Dif-
ferences in AMP expression between periodontitis patients and
healthy subjects has been identified using proteomic analyses.96
Understanding the role of individual AMPs in oral disease may
lead to the development of disease biomarkers and new therapies.
AMPs also differ markedly in their antimicrobial activity against
different oral species.97 For example, the antimicrobial effects of
adrenomedullin can vary considerably, with both fully resistant
and sensitive (minimum inhibitory concentrations down to
< 0.1 mg/ml) oral anaerobic species / strains.98 When such MIC
values are compared to concentrations of AM found in the gingi-
val crevicular fluid (GCF) of patients with periodontal disease
(approx. 1-2 mg/ml),99 it is clear that adrenomedullin has the
potential to influence the growth of the oral microflora in vivo.
Systems are being developed to target AMPs against given oral
species using a targeting peptide, linker region and antimicrobial
peptide component.100,101 Other approaches include the modifi-
cation of natural peptides to generate peptides with more favor-
able efficacy/toxicity profiles.102 Alternatively, peptide mimetics
have been designed and synthesized which retain the biological
activity of an AMP but are advantageous as regards production
costs, possess favorable therapeutic index and show stability
under physiological conditions.103 For example, mimetics based
upon the defensin structure have demonstrated a high therapeutic
index in pre-clinical studies.104 With regards to the oral cavity,
the development of novel antimicrobials should allow control of
pathogens without loss of beneficial commensals.105 Approaches
that stimulate or restore the normal expression patterns of AMPs,
rather than being used as exogenous therapeutic agents, may be
particularly useful in the prevention of periodontal disease. For
example, through the use of receptor activation or through the
use of protease inhibitors to improve the longevity of AMPs or
related receptors.106 As with other agents, a combination of
AMP use and mechanical debridement is likely to be most suc-
cessful in the control of periodontitis.
Nanotechnology
Nanotechnology represents the ability to image, manipulate
and model functionalities on the nanometer scale.107 This disci-
pline includes the use of nanoparticles which can be classified as
particles of a size less than 100 nm. Properties of nanoparticles,
for example, their active surface area, chemical reactivity and bio-
logical activity, are often far removed from those of a greater size.
These characteristics should allow them to closely interact with
microbial surfaces, and thus elicit an antimicrobial effect that is
not solely due to released components. Metallic and other nano-
particles are now being combined with polymers and other base
materials, and coated onto surfaces to ultimately provide a variety
of potential applications within the oral cavity. The use of nano-
technology offers the possibility to control the formation of oral
biofilms through the application of nanoparticles with biocidal,
anti-adhesive and delivery capabilities.108
Nanoparticle based implant coatings should also offer both
osteoconductive and antimicrobial functionalities to prevent den-
tal implant failure. Such implant systems are increasingly being
used to replace missing teeth, and most integrate with bone with-
out complications. The condition peri-implantitis is a major
cause of dental implant failure whereby the induced inflamma-
tory changes in the soft tissues surrounding the implant lead to a
progressive destruction of the supporting bone.3 Current forms
of treatment are often inadequate, with chronic infection often
requiring implant removal and expensive resective and regenera-
tive procedures in an attempt to restore and reshape the support-
ing tissue.109
Antimicrobial nanoparticles and control of oral biofilms
Metals have been used for centuries as antimicrobial agents.
Silver, copper, gold, titanium and zinc have attracted particular
attention, each having different properties and spectra of activity.
Indeed, many oral products, including toothpastes, now incorpo-
rate powdered (micron-sized) zinc citrate or acetate to control
Table 3. Functional classes of antimicrobial peptides and proteins (with examples) found in the oral cavity
Cationic
peptides
Bacterial
agglutination and
adhesion Metal ion chelators Peroxidases Protease inhibitors
Activity against bacterial
cell walls
Adrenomedullin b-2-microglobulin Calgranulins A & B Lactoperoxidase Cystatins Lysozyme
b defensins 1-3 Fibronectin Lactoferrin Myeloperoxidase Secretory leukoprotease
inhibitor protein
Peptidoglycan recognition
proteins
Cathelicidin (LL-37) Proline-rich proteins Psoriasin
Histatins 1 and 3 Transferrin
Neutrophil (a)
defensins 1-4
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the formation of dental plaque.110 With respect to nanoparticu-
late metals, the antimicrobial properties of silver111 and cop-
per112 have received the most attention. Both of these have been
coated onto or incorporated into various test materials, including
the denture material Poly (methyl methacrylate) (PMMA).113
Nanoparticulate metal oxides have been of particular interest
as antimicrobial agents as they can be prepared with extremely
high surface areas and unusual crystal morphologies that have a
high number of edges, corners and other potentially reactive
sites.114 On the other hand, certain metal oxides are now coming
under close scrutiny because of their potential toxic effects to
eukaryotic cells.115 Oxides under consideration as antimicrobial
agents include those of copper, zinc, titanium and tungsten.
Studies have shown that some nanoparticulate metal oxides, such
as ZnO, have a degree of selective toxicity to bacteria with a min-
imal effect on human cells at the concentrations employed.116
Bacteria are far less likely to acquire resistance to metal nanopar-
ticles than they are to other conventional and narrow-spectrum
antibiotics. This is thought to occur because metals may act on a
broad range of microbial targets, and many mutations would
have to occur in order for the microorganisms to resist their anti-
microbial activity.117
Quaternary ammonium poly (ethylene imine) (QA-PEI) anti-
microbial nanoparticles have also been developed and incorpo-
rated into dental composite resins.118 This approach may be
particularly beneficial when compared to the currently used com-
posite resins for hard tissue restoration, which are known to pos-
sess several disadvantages including development of biofilms on
both teeth and the restorative material.
Anti-adhesive nanoparticles and oral biofilm control
Particles of a nano and micro size based upon the element sili-
con have been designed to rapidly deliver antimicrobial and anti-
adhesive capabilities to the desired site within the oral cavity.119
Companies use silica (often classed as ‘micro fine’, but with a par-
ticle size within the definition of nanoparticles) in toothpastes,
and some have actively sought new directions in this area through
the use of porous silicon and nanocrystalline silicon technology
to carry and deliver antimicrobials, for example, triclosan. Other
systems based upon silica have been investigated with respect to
the control of oral biofilms. The use of nitric oxide-releasing sil-
ica nanoparticles to eradicate biofilm growth has been described.
Bioactive glasses of the SiO2-Na2O-CaO-P2O5 system have been
shown to possess antimicrobial activity through the release of
ionic alkaline species over time.120 Those in the form of amor-
phous nanoparticles, with a size range of 20 to 60 nm, may show
an advantage over micron-sized material as the decrease in glass
particle size should increase the active exchange surface of glass
and surrounding liquid. This should then substantially increase
ionic release into suspension and enhance antimicrobial efficacy.
Chitosan, a biopolymer derived by the deacetylation of chitin
occurring in the exoskeleton of crustaceans is positively charged
and soluble in acidic to neutral solution, enabling it to bind to
mucosal surfaces. Both chitosan nano- and microparticles have
been investigated as a potential platform for local delivery of
drugs within the oral cavity.121
The application of nano-scaled hydroxyapatite (nHA) par-
ticles has been shown to impact on oral biofilm formation and
can also provide a re-mineralization capability. Biomimetic
approaches based upon HA nanocrystals which resemble the
structure at the nano-scale of abraded dental enamel crystallites,
in theory should allow adsorbed particles to interact with bacte-
rial adhesins, reduce bacterial adherence and hence impact on
biofilm formation.122 A number of oral health care products,
including toothpastes and mouth rinses, have been developed
containing nano-sized apatite particles with and without protein-
based additives.123,124 It is suggested that the efficacy of these
compounds can be attributed to the size-specific effects of the
apatite nanoparticulates. Casein phosphopeptide (CPP)—amor-
phous calcium phosphate (ACP) nanocomplex (RecaldentTM/
MI PasteTM) is a particular technology based upon ACP and sta-
bilized by casein phosphopeptide (CPP).125 Use of this technol-
ogy has demonstrated anticariogenic activity under both in vitro
and in vivo test conditions. With reference to dental implants,
numerous companies market synthetic HA materials as the
‘optimal’ osteoconductive implant coating available and some
companies have developed nano-scaled varieties. Furthermore,
combined nHA and nano zinc oxide (nZnO) coatings have
shown much potential as regards antimicrobial activity and
biocompatibility.116
Biocompatibility of nanoparticles within the oral cavity
Although the development and application of nanotechnology
is of considerable interest, knowledge regarding the possible tox-
icity of nanotechnology products to humans is limited. In order
to fully understand the mechanism of toxicity, a thorough knowl-
edge of the toxico-kinetic properties of nanoparticles is required.
Toxicology and biodynamic studies do suggest that silica, silicon,
and chitosan nanoparticles are relatively safe if introduced via the
oral route.126 The safe use of nanotechnology and the design of
nanomaterials for biological applications involve a thorough
understanding of the interface between these materials and bio-
logical systems.127 The nanoparticle characteristics of most
importance as regards interaction with biological systems,
whether mammalian or microbial, are chemical composition,
surface function, shape and number of sides, porosity and surface
crystallinity, size heterogeneity, roughness, and hydrophobicity
or hydrophilicity.128 In order to help prevent aggregation of
nanoparticles, stabilizing (capping) agents that bind to the entire
nanoparticle surface can be used; these include water-soluble pol-
ymers, oligo- and poly-saccharides, sodium dodecyl sulfate, poly-
ethylene glycol and glycolipids.129 An understanding of the
interface between biological systems and nanomaterials should
enable design features to be used to control the exposure, bio-
availability and biocatalytic activities. A number of possible
approaches are starting to be identified including changing the
ability to aggregate, application of surface coatings, and altering
charge density and oxidative state. However this may well com-
promise the intended selective toxicity of antimicrobial nanopar-
ticles. It remains to be determined how potential mammalian
toxicity issues will fully impact on the use of nanotechnology in
the control of oral infections.
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Conclusions
Further studies, including investigations into the cost effec-
tiveness, specificity, safety aspects and patient acceptance of
using non-conventional approaches in the control of oral
infections will be required. Such strategies should ideally
reduce plaque levels without affecting the overall biological
equilibrium within the oral cavity. Selective light-activated
killing, functional inhibition of specific virulence factors and
microbial replacement therapy offer a more targeted approach,
whereas the use of plaque disrupting agents, antimicrobial
peptides and nanoparticles are relatively more general.
Approaches that offer complementary modes of action will
increase antimicrobial effectiveness when used in combination,
particularly when improved delivery systems are employed.
The increasing consumer demand for effective and safe oral
care products will help to further drive the need to investigate
non-conventional therapeutics.
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